American joint committee on cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome

Journal of the National Cancer Institute

Volumn 97, Issue 15, 2005, Pages 1137-1142

  Carey, Lisa A ^a   Metzger, Richard ^b   Dees, E Claire ^a   Collichio, Frances ^a   Sartor, Carolyn I ^a   Ollila, David W ^a   Klauber DeMore, Nancy ^a   Halle, Jan ^a   Sawyer, Lynda ^b   Moore, Dominic T ^b,c   Graham, Mark L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CLASSIFICATION; DISEASE FREE SURVIVAL; LYMPH NODE; LYMPHADENECTOMY; MASTECTOMY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 23244444652     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji206     Document Type: Article

References (8)

1. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
2. Cance WG, Carey LA, Calvo BF, Sartor C, Sawyer L, Moore DT. et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 2002;236:295-302; discussion 302-3.
3. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.
4. Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual. 6th ed. New York (NY):Springer;2002.
5. Carey LA, Dees EC, Sawyer L, Moore DT, Dressler L, Cowan D, et al. Response to trastuzumab (Herceptin) given with paclitaxel (Taxol) immediately following 4AC as initial therapy for primary breast cancer. Breast Cancer Res Treat 2002;76:424.
6. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93-100.
7. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B. Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N. The effect on rumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. JCO 2003;21:4165-74.
8. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-66.